Selumetinib, a selective MEK1 inhibitor, increases the killing effect of everolimus in RCC [57], and the combination of MEK inhibitor cobimetinib and cabozantinib reduces drug resistance of RCC [58]. Here, MAP2K7 is linked to renal cell carcinoma.